Copaxone PBAC submission – July 2017 - MS Australia

About Us
For People with MS
FOR RESEARCHERS
Research
Advocacy
Get Involved

Menu

About Us
For People with MS
FOR RESEARCHERS
Research
Advocacy
Get Involved

NEWS
PODCAST
RESOURCES
VIDEOS
CONTACT

About Us
For People with MS
FOR RESEARCHERS
Research
Advocacy
Get Involved

Menu

About Us
For People with MS
FOR RESEARCHERS
Research
Advocacy
Get Involved

Medication Subsidy (PBAC), Medications and Treatments, Disease Modifying Therapy, DMT, Pharmaceutical Benefits Advisory Committee, PBAC

Copaxone PBAC submission – July 20172017-07-012024-09-03https://msra.org.au/wp-content/uploads/2016/03/MSRA-logo.jpgMS Australiahttps://msra.org.au/wp-content/uploads/2016/03/MSRA-logo.jpg200px200px

registered charity

1300 010 158

info@msaustralia.org.au

Suite 3.01, 18 Flour Mill Way
Summer Hill NSW 2130

Participate in MS Research

MS Clinical Trials
MS Australia Brain Bank
Australian MS Longitudinal Study

Facebook-f X-twitter Linkedin-in Youtube Spotify Paper-plane

Quick links

What is MS?
How is MS diagnosed?
COVID-19 and MS
Research funding opportunities
Research we fund
Media enquiries
Contact us

© 2025 Multiple Sclerosis Australia | ABN: 51 008 515 508 │Privacy Policy | Whistleblower Policy | Complaints Policy | Terms and Conditions

© 2024 Multiple Sclerosis Australia

ABN: 51 008 515 508

Privacy Policy | Whistleblower Policy
Complaints Policy | Terms and Conditions

Read More

Glatiramer acetate (Copaxone) for Clinically Isolated Syndrome – PBAC Review

Ocrelizumab PBAC submission – July 2017

Search ...

Newsletter subscription

What would you like to hear about?*
- MS Australia
- Kiss Goodbye to MS
Enter your details
Title*
First Name*
Last Name*
Email*

Δ

Copaxone PBAC submission – July 2017